Bristol-Myers Squibb has been granted a patent for antibodies that bind to CD40, including a humanized antibody. These antibodies do not have CD40 agonist activity and exhibit minimal activation of immature dendritic cells. The patent also covers compositions comprising these antibodies and their use in the treatment of diseases involving CD40 activity. The patent includes a specific nucleic acid molecule encoding the antibody with defined sequences for the heavy and light chain variable regions. GlobalData’s report on Bristol-Myers Squibb gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bristol-Myers Squibb, Cancer treatment biomarkers was a key innovation area identified from patents. Bristol-Myers Squibb's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a nucleic acid molecule encoding cd40 antibody
A recently granted patent (Publication Number: US11773178B2) discloses a nucleic acid molecule that encodes an isolated antibody or antigen binding portion that specifically binds to human CD40. The antibody consists of a heavy chain variable region and a light chain variable region. The heavy chain variable region includes three complementarity-determining regions (CDRs) with specific sequences, while the light chain variable region includes three CDRs with different specific sequences.
The patent also describes an expression vector that contains the nucleic acid molecule encoding the antibody or antigen binding portion. Additionally, a cell transformed with this nucleic acid is claimed.
The patent further provides a method for preparing the anti-human CD40 antibody or antigen binding portion. This method involves expressing the antibody in the transformed cell and isolating it from the cell.
The nucleic acid molecule described in the patent can produce an antibody or antigen binding portion that antagonizes the activity of CD40.
The heavy chain variable region of the antibody can have a specific amino acid sequence, while the light chain variable region can have a different specific amino acid sequence.
The first polypeptide portion of the antibody includes a human heavy chain constant region, and the second polypeptide portion includes a human light chain constant region.
The human heavy chain constant region can have a mutation at Kabat position 238, which reduces binding to Fc-gamma-receptors (Fc?Rs). This mutation involves substituting proline 238 (P238) with one of several specific residues. The antibody or antigen binding portion with this mutation exhibits reduced Fc?R binding. Alternatively, the human heavy chain constant region can have an alanine substitution at Kabat position 297.
The patent also covers a human IgG1 Fc domain with the mutation at Kabat position 238, where P238 is mutated to lysine. The Fc domain can have specific amino acid sequences.
Other embodiments of the nucleic acid molecule include humanized antibodies or antigen binding portions, scFv-Fc antigen binding portions, and linked therapeutic agents or second functional moieties with different binding specificities.
The patent also allows for the inclusion of an additional moiety in the nucleic acid molecule.
Overall, this granted patent provides valuable information on the nucleic acid molecule encoding an antibody or antigen binding portion that specifically binds to human CD40, along with various embodiments and applications of this molecule.
To know more about GlobalData’s detailed insights on Bristol-Myers Squibb, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
